IMS CORE lab teams up with Cristal Therapeutics
Cristal Therapeutics has announced that it has secured a Horizon 2020 grant. This allows the company to further develop the CriPec Nanomedicine Platform. This will be done in collaboration with the IMS CORE lab at Maastricht University’s M4I Division of Imaging Mass Spectrometry.
Cristal Therapeutics is a phase 2 clinical-stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases. The ICARUS project will be carried out in close collaboration with the IMS CORE lab at the division of Imaging Mass Spectrometry, where CriPec® nanoparticle microlocalisation and drug release in tumours will be evaluated. Mass spectrometry imaging, technology together with Cristal Therapeutics’ expert team, will provide critical new insights to optimally design CriPec® nanomedicines with the aim of achieve superior therapeutic profiles.
The project at M4I will be led by Dr. Berta Cillero Pastor and by Prof. Ron Heeren.
For more details, read the full article on the Cristal Therapeutics website: http://cristaltherapeutics.com/cristal-therapeutics-awarded-horizon-2020-grant-to-further-develop-the-cripec-nanomedicine-platform/
Also read
-
Contribute to a Voice for Children in Conflict Areas
Dr Marieke Hopman and Guleid Jama are launching a new research project on the role of children in peacebuilding in conflict areas.
-
Administrative integration through agency governance The role of Frontex, the EUAA and Europol
PhD thesis by Aida Halilovic
-
The University Fund Limburg's new Annual Fund Campaign is live!
Every year during the holiday season, the UM community comes together to uphold a special tradition: supporting projects that contribute to a healthier, fairer and more sustainable society. Will you join us?
